Wikidata

(Q56995760)

English

Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL

article by Simona Soverini et al published March 2007 in Lancet Oncology Commission

In more languages

Statements

title
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL (English)
0 references
author
Michela Rondoni
object named as
Michela Rondoni
series ordinal
5
0 references
Simona Soverini
object named as
Simona Soverini
series ordinal
1
0 references
Gianantonio Rosti
series ordinal
8
object named as
Gianantonio Rosti
0 references
Fausto Castagnetti
series ordinal
6
object named as
Fausto Castagnetti
0 references
Giovanni Martinelli
series ordinal
2
object named as
Giovanni Martinelli
0 references
Michele Baccarani
series ordinal
9
object named as
Michele Baccarani
0 references
Stefania Paolini
series ordinal
7
object named as
Stefania Paolini
0 references
Alessandra Gnani
series ordinal
4
object named as
Alessandra Gnani
0 references
Sabrina Colarossi
series ordinal
3
object named as
Sabrina Colarossi
0 references
publication date
March 2007
0 references
volume
8
0 references
issue
3
0 references
page(s)
273-4
0 references
cites work

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q56995760&oldid=1747738997"